←
Cerevance245 posts
Cerevance avatar

Cerevance

@cerevance

Creating a world-class neuroscience company to advance new medicines for serious diseases

◷ Joined December 2018▧ 124 Photos and videos
Cerevance avatar
Cerevance@cerevance·Oct 26

Last week, our CEO Craig Thompson joined fellow neuroscience leaders and investors at the @GoldmanSachs Healthcare Private Company Conference to discuss new approaches to neurodegenerative disorders and share findings from our Phase 3 ARISE study in Parkinson’s disease.

Post attachment
Cerevance avatar
Cerevance@cerevance·May 12

Big milestone: We’ve fully enrolled 341 patients in the Phase 3 ARISE trial of solengepras—a potential first-in-class, non-dopaminergic therapy for Parkinson's—and closed a $20M Series C to fund us through topline data this year. bit.ly/3Pd7IcS #Biotech #ClinicalTrials

0:21
Cerevance avatar
Cerevance@cerevance·Apr 23

We’re inspired by the vibrant scientific exchange across the neurology community at #AANAM. Phase 2 solengepras data, presented by Drs. Sarva and Hauser, showed meaningful reductions in OFF time and improvement in sleep-related symptoms in #PD. Learn more: bit.ly/41MiFoq

Post attachmentPost attachment
Cerevance avatar
Cerevance@cerevance·Apr 20

OFF time. Sleep disturbance. Daily unpredictability. Phase 2 solengepras data showed the potential impact of targeting GPR6 to address these non-motor outcomes, marking a shift in how we treat #PD. Phase 3 results are coming later this year. Learn more: bit.ly/48aJOF3

Cerevance avatar
Cerevance@cerevance·Apr 9

We’re heading to #AANAM to present Phase 2 data for solengepras showing reductions in OFF time and improvements in sleep in #Parkinsons disease. Learn about our presentations: bit.ly/3PYWybJ

0:15
Cerevance avatar
Cerevance@cerevance·Mar 10

We’re presenting new Phase 2 data for solengepras, our investigational oral GRP6 inhibitor, at #ADPD2026 in Copenhagen. Learn how our science aims to expand treatment options: bit.ly/4dd8pwc

0:13
Cerevance avatar
Cerevance@cerevance·Mar 2

Our Parkinson’s research is grounded in science and strengthened by partnerships. We were proud to stand with the PD community at the MJFF Los Angeles Run/Walk, united by a shared commitment to advancing progress in PD. Get involved with @MichaelJFoxOrg: bit.ly/4shp1XQ

Post attachmentPost attachment
Cerevance avatar
Cerevance@cerevance·Feb 23

We’re excited to connect with the neuroscience community at the TD Cowen 46th Annual Health Care Conference in Boston next week, where our leadership team will meet with investors to share updates on our latest research in neurodegenerative diseases: bit.ly/40pdxpr

0:13
Cerevance avatar
Cerevance@cerevance·8 Dec 2025

At Cerevance, we’re aiming to provide a new treatment option for individuals with #PD that shifts beyond dopamine, offering an entirely differentiated mechanism of action that can better improve daily life experiences. Read about it in @FierceBiotech: bit.ly/3MN2v9O

Cerevance avatar
Cerevance@cerevance·6 Dec 2025

We’re excited to present new data from our Phase 2 adjunctive study of solengepras at the #PSG2025 Annual Meeting today. Discover how solengepras demonstrated significant reductions in OFF time in individuals with #Parkinsons disease: bit.ly/3YbpJZL

0:17
Cerevance avatar
Cerevance@cerevance·24 Nov 2025

Advancing Parkinson’s care with a novel, non-dopaminergic approach. Next week at the PSG Annual Meeting in San Diego, we’re excited to showcase solgenepras and its potential to address unmet needs in Parkinson’s disease. Learn about our presentations: bit.ly/4olH2lD

0:19
Cerevance avatar
Cerevance@cerevance·17 Nov 2025

We’re excited to share our latest research in obesity and neurodegenerative disorders driven by #neuroinflammation at the upcoming TD Cowen Treatment Advancements in Obesity and Related Disorders Summit. Learn about our panel discussion: bit.ly/3XwC2zs

0:19
Cerevance avatar
Cerevance@cerevance·13 Oct 2025

We had a great time connecting with the global movement disorders community at last week’s #MDSCongress, where we presented findings from our Phase 2 ASCEND trial of solengepras. Learn more about how we’re driving innovation in #PD research: bit.ly/3J6u7oZ

Post attachment
Cerevance avatar
Cerevance@cerevance·22 Sep 2025

Join us at the 2025 #MDSCongress in Honolulu, where we’ll present the promising findings from our Phase 2 ASCEND trial of solengepras in patients with early, untreated #PD. Learn more about our oral presentation: bit.ly/3ICx14F We hope to see you there!

0:19